Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

NCT04158440 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

501

Enrollment

OTHER

Sponsor class

Conditions

Stage II-III Non-small Cell Lung Cancer

Interventions

DRUG: 4cycles(Toripalimab IV 240mg + platinum-based doublet chemotherapy)+13 cycles(Toripalimab IV 240mg); Biological: Toripalimab
DRUG: 4cycles(Placebo + platinum-based doublet chemotherapy)+13 cycles(Placebo )

Sponsor

Shanghai Junshi Bioscience Co., Ltd.